

Date: October 25, 2024

Ref. No.: KDL/SE/100/2024-25

To, BSE Limited Corporate Relationship Department 25th Floor, Phiroze Jeejeebhoy Towers Dalal Street, Mumbai- 400001 Scrip Code: 543328	To, National Stock Exchange of India Limited Exchange Plaza, Plot No. C-1, Block G, Bandra Kurla Complex, Bandra (East) Mumbai – 400051 NSE Symbol: KRSNAA
--	---

Subject: Outcome of Board Meeting held on October 25, 2024.

In compliance with Regulation 30 read with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we would like to inform you that the Board of Directors of the Company at its meeting held today i.e. October 25, 2024 inter-alia approved and/or took note of the following items:

- Unaudited (Standalone and Consolidated) Financial Results for the quarter and half year ended September 30, 2024;
- Limited Review Report for quarter and half year ended September 30, 2024.

The Board Meeting commenced at 17:00 Hrs. (IST) and concluded at 20:20 Hrs. (IST).

The aforesaid results are also being disseminated on Company's Website. This is for your information and records.

Thanking You

For Krsnaa Diagnostics Limited



Sujoy Sudipta Bose
Company Secretary and Compliance Officer
Encl: As above



Independent Auditor's Review Report on Standalone unaudited financial results of Krsnaa Diagnostics Limited for the quarter and year to date pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To the Board of Directors of Krsnaa Diagnostics Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results of Krsnaa Diagnostics Limited (hereinafter referred to as 'the Company') for the quarter ended September 30, 2024 and the year to-date results for the period from April 01, 2024 to September 30, 2024 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We draw attention to Note No. 7 of the unaudited financial results in respect of additions made by the Income Tax Authorities, consequent to an assessment order passed and a demand raised on the Company for the assessment year ("AY") 2022-23 in relation to search assessment proceedings conducted under section 132(1) and section 133A of the Income Tax Act, 1961. The Company has filed an appeal with the Joint Commissioner (Appeals) or Commissioner of Income Tax (Appeals) against the said Order and has deposited Rs. 39.26 million as tax under protest, as required by law during the half year ended September 30, 2024. As there is uncertainty on the ultimate outcome of the assessment proceedings and the appeal filed by the Company, the impact on the previous period financial statements and on the current period financial results for the quarter and the half year ended September 30, 2024, including income tax, interest and other charges if any, is currently unascertainable.



MSKA & Associates

Chartered Accountants

Our conclusion is not modified in respect of the above matter.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No.105047W



Vikram Dhanania
Partner
Membership No.: 060568
UDIN: 24060568BKDZKX3355

Place: Mumbai
Date: October 25, 2024

1. Statement of Unaudited Standalone Financial Results for the quarter and half year ended September 30, 2024

(INR Million, except earnings per share)

Sr. No.	Particulars	Quarter ended			Half year ended		Year ended
		September 30, 2024	June 30, 2024	September 30, 2023	September 30, 2024	September 30, 2023	March 31, 2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income						
	Revenue from operations	1,787.22	1,631.63	1,468.52	3,418.85	2,791.37	5,900.19
	Other income	46.04	73.17	41.58	119.22	83.80	167.96
	Total Income	1,833.26	1,704.80	1,510.10	3,538.07	2,875.17	6,068.15
2	Expenses						
	Cost of material consumed	449.13	429.01	359.16	878.14	636.85	1,410.40
	Employee benefits expense	281.12	287.65	228.18	568.77	424.19	975.69
	Finance costs	63.87	53.03	30.58	116.90	50.12	164.66
	Depreciation and amortization expense	222.01	214.66	194.64	436.67	351.99	745.47
	Fees to hospitals and others	170.67	123.41	181.93	294.08	339.46	609.34
	Other expenses	361.50	361.76	373.78	723.26	743.56	1,443.14
	Total Expenses	1,548.30	1,469.52	1,368.27	3,017.82	2,546.17	5,348.70
3	Profit before tax (1) - (2)	284.96	235.28	141.83	520.25	329.00	719.45
4	Tax expenses						
	Income Tax charge	51.03	39.95	16.97	90.99	55.16	114.42
	Income Tax charge relating to earlier period	-	-	-	-	(6.26)	(6.41)
	Deferred tax charge/(credit)	14.28	13.52	11.78	27.80	14.50	25.83
	Total tax expenses	65.31	53.47	28.75	118.79	63.40	133.84
5	Profit for the period (3) - (4)	219.65	181.81	113.08	401.46	265.60	585.61
6	Other comprehensive income						
	Items that will not be reclassified subsequently to profit and loss:						
	Re-measurement gains on defined benefit plans	(0.65)	(0.70)	2.16	(1.35)	4.32	(2.44)
	Income tax effect	0.16	0.18	(0.54)	0.34	(1.08)	0.61
	Total other comprehensive income for the period	(0.49)	(0.52)	1.62	(1.01)	3.24	(1.83)
7	Total comprehensive income for the period, net of tax (5+6)	219.16	181.29	114.70	400.45	268.84	583.78
8	Paid-up equity share capital (Face Value of Rs. 5/- each)	161.45	161.45	156.99	161.45	156.99	161.45
	Other equity						7,990.96
	Earnings per share (Not annualised for quarters):						
	Basic (Rs.)	6.80	5.63	3.60	12.43	8.46	18.45
	Diluted (Rs.)	6.64	5.54	3.48	12.18	8.16	17.83

For and on behalf of Board of Directors
Krsnaa Diagnostics Limited

Rajendra Mutha

Rajendra Mutha
Chairman & Whole-time Director
DIN: 01066737



Place: Goa
Date: October 25, 2024

2. Statement of Unaudited Standalone Assets & Liabilities as at September 30, 2024

(INR Million)

Particulars	As at September 30, 2024 (Unaudited)	As at March 31, 2024 (Audited)
I. ASSETS		
Non-current assets		
Property, plant and equipment	6,863.38	6,447.21
Capital work-in-progress	34.76	98.45
Intangible assets	23.24	24.34
Financial assets		
Investments	3.71	3.61
Other financial assets	1,233.93	326.55
Other non-current assets	588.36	591.40
Total non-current assets	8,747.38	7,491.56
Current assets		
Inventories	306.87	358.07
Financial assets		
Trade receivables	2,464.31	1,780.66
Cash and cash equivalents	101.79	18.58
Bank balances other than cash and cash equivalent	513.44	511.70
Other financial assets	638.38	1,430.51
Other current assets	175.44	124.57
Total current assets	4,200.23	4,224.09
Total Assets	12,947.61	11,715.65
II. EQUITY AND LIABILITIES		
Equity		
Equity share capital	161.45	161.45
Other equity	8,326.89	7,990.96
Total equity	8,488.34	8,152.41
Liabilities		
Non-current liabilities		
Financial liabilities		
Borrowings	27.50	55.00
Lease Liabilities	321.20	363.81
Other financial liabilities	160.44	205.59
Employee benefit obligations	17.51	14.49
Deferred Tax Liabilities	196.79	163.84
Total non-current liabilities	723.44	802.73
Current liabilities		
Financial liabilities		
Borrowings	1,662.19	1,012.21
Lease Liabilities	149.99	166.86
Trade payables		
i) Total outstanding dues of micro enterprises and small enterprises	8.59	6.65
ii) Total outstanding dues of creditors other than micro enterprise and small enterprise	882.83	778.58
Other financial liabilities	954.68	667.48
Other current liabilities	29.66	90.53
Employee benefit obligations	47.89	38.20
Total current liabilities	3,735.83	2,760.51
Total Liabilities	4,459.27	3,563.24
Total Equity and Liabilities	12,947.61	11,715.65

For and on behalf of Board of Directors
Krsnaa Diagnostics Limited



Rajendra Mutha
Chairman & Whole-time Director
DIN: 01066737

3. Statement of Unaudited Standalone Cashflows for the half year ended September 30, 2024

Particulars	(INR Million)		
	Half Year Ended	Half Year Ended	Year Ended
	September 30, 2024	September 30, 2023	March 30, 2024
	(Unaudited)	(Unaudited)	Audited
A. Cash flow from operating activities			
Profit for the period	520.25	329.00	719.45
Adjustments for:			
Depreciation and amortization expenses	436.67	351.99	745.47
Employee stock option scheme compensation	21.69	2.60	9.01
Finance cost	116.90	50.12	164.66
Interest income on deposits	(75.52)	(76.03)	(152.32)
Loss / (Gain) on sale/disposal of Property, Plant & Equipment	0.29	(0.01)	0.53
Provision for credit Impaired/(Reversal in provision for credit impairment)	2.00	-	3.40
Amortisation of deferred revenue	(0.06)	(0.74)	(1.19)
Amortisation of prepaid rent	8.34	-	(56.51)
Interst Income on other Financial Assets	(7.85)	-	(14.07)
Operating profit before working capital changes	1,022.71	656.93	1,418.43
Changes in working capital			
Increase/(Decrease) in trade payables	93.04	394.94	147.65
(Increase)/Decrease in inventories	51.20	(113.56)	(107.33)
(Increase)/Decrease in trade receivables	(687.85)	(850.97)	(1,041.52)
Increase/(Decrease) in other current liabilities	(58.69)	6.06	69.93
Increase/(Decrease) in other non current liabilities	0.07	3.42	-
Increase/(Decrease) in other current financial liabilities	0.15	274.19	41.14
Increase/(Decrease) in other non current financial liabilities	(0.00)	(278.04)	23.72
Increase/(Decrease) in employee payables	11.35	9.25	20.10
(Increase)/(Decrease) in other current financial assets	58.21	(63.36)	(29.46)
(Increase)/Decrease in non current financial assets	(87.42)	52.87	(9.87)
(Increase)/Decrease in other current assets	(37.72)	(90.37)	(11.07)
(Increase)/Decrease in other non current assets	(87.25)	65.40	(89.75)
Cash generated from operations	277.82	66.76	431.97
Income tax paid (net of refund)	(74.91)	(68.54)	(188.03)
Net cash flows generated from operating activities (A)	202.91	(1.78)	243.94
B. Cash flow from Investing activities			
Payment for property, plant and equipment and intangible assets	(546.43)	(899.37)	(1,938.87)
Proceeds from sale of property, plant and equipment and intangible assets	0.39	0.04	8.87
Investment in term deposits with banks	(112.94)	463.64	537.40
Loan to Subsidiaries [net]	(11.82)	-	-
Investment in equity instrument of Subsidiary	(0.10)	-	-
Interest received	112.01	49.24	103.83
Net cash flow used in investing activities (B)	(558.89)	(386.45)	(1,288.77)
C. Cash flow from Financing activities			
Proceeds from Exercise of ESOP	-	-	231.92
Proceeds of Short Term borrowings (net)	649.98	534.14	957.21
Repayment of Long Term borrowings	(27.50)	-	(55.00)
Lease liabilities paid	(82.72)	(41.49)	(81.90)
Dividend payment/TDS on dividend to equity shareholders	(5.27)	-	(86.29)
Interest paid	(95.30)	(30.91)	(123.85)
Net cash flow generated used in financing activities (C)	439.19	461.74	842.09
Net Decrease in cash and cash equivalents (A+B+C)	83.21	73.51	(202.74)
Cash and cash equivalents at the beginning of the year	18.58	221.32	221.32
Cash and cash equivalents at the end of the year	101.79	294.83	18.58
Cash and cash equivalents comprise:			
Balances with banks			
On current accounts	86.90	285.16	7.63
Debit balance in bank overdraft	-	0.00	-
Cash on hand	14.89	9.67	10.95
Total cash and bank balances at end of the year	101.79	294.83	18.58

For and on behalf of Board of Directors
Krsnaa Diagnostics Limited



Rajendra Mutha
Chairman & Whole-time Director
DIN: 01066737

Place: Goa
Date: October 25, 2024

Krsnaa Diagnostics Limited
CIN:L74900PN2010PLC138068

Notes to Unaudited Standalone Financial Results:

4. These standalone unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on October 25, 2024.

5. The above Statement has been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) 2015, as amended.

6. The Company's operations predominantly relate to providing diagnostic services in radiology and pathology services. The Chief Operating Decision Maker (CODM) reviews the operations of the Company as one operating segment. Hence, no separate segment information has been furnished herewith.

7. Pursuant to search and seizure proceedings initiated under the provisions of section 132(1) and section 133A of the Income Tax Act, 1961 on the Company on July 20, 2022, an assessment order dated March 31, 2024 u/s 143(3) of the Income Tax Act, 1961 ("the Order"), has been received by the Company for the assessment year ("AY") 2022-23. The Income tax authorities have allegedly made additions on account of undisclosed income and disallowance of certain deductions claimed by the Company in the tax returns filed in respect of AY 2022-23 and raised a demand of Rs.196.3 million.

The Company has provided the requisite disclosure to the stock exchange on July 29, 2022, with respect to the search operations, and on April 1, 2024, with respect to the receipt of the Order in accordance with Regulation 30 of the SEBI (LODR) Regulations, 2015 (as amended). The Company has filed an appeal with the Joint Commissioner (Appeals) or Commissioner of Income-Tax (Appeals) against the Order on April 29, 2024, and have paid tax under protest on August 6, 2024, amounting to Rs. 39.26 million.

The management of the Company, based on available information, underlying evidence and opinion from tax consultants and experts, is of the view that the said demand is not tenable and will not have any material impact on the Company's financial position as of September 30, 2024, and on its performance for the quarter and half year ended on that date.

8. Previous period/year figures have been regrouped/ rearranged wherever considered necessary.

Place: Goa
Date: October 25, 2024



For and on behalf of Board of Directors
Krsnaa Diagnostics Limited

Rajendra Mutha
Chairman & Whole-time Director
DIN: 01066737

Independent Auditor’s Review Report on consolidated unaudited financial results of Krsnaa Diagnostics Limited for the quarter and year to date pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Krsnaa Diagnostics Limited

1. We have reviewed the accompanying Statement of consolidated unaudited financial results of Krsnaa Diagnostics Limited (hereinafter referred to as ‘the Holding Company’) and its subsidiaries, (the Holding Company and its subsidiaries together referred to as the ‘Group’) for the quarter ended September 30, 2024, and the year to-date results for the period from April 01, 2024 to September 30, 2024 (‘the Statement’) attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (‘the Regulations’).
2. This Statement, which is the responsibility of the Holding Company’s Management and approved by the Holding Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 ‘Interim Financial Reporting’ prescribed under Section 133 of the Companies Act, 2013 (‘the Act’) read with relevant rules issued thereunder (‘Ind AS 34’) and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, ‘Review of Interim Financial Information Performed by the Independent Auditor of the Entity’ issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Regulations, to the extent applicable.

4. This Statement includes the results of the Holding Company and the following entities:

Sr. No	Name of the Entity	Relationship with the Holding Company
1	Krsnaa Diagnostics (Mohali) Private Limited	Wholly Owned Subsidiary
2	KDPL Diagnostics (Amritsar) Private Limited	Wholly Owned Subsidiary



Sr. No	Name of the Entity	Relationship with the Holding Company
3	KDPL Diagnostics (Bathinda) Private Limited	Wholly Owned Subsidiary
4	KDPL Diagnostics (Jalandhar) Private Limited	Wholly Owned Subsidiary
5	KDPL Diagnostics (Ludhiana) Private Limited	Wholly Owned Subsidiary
6	KDPL Diagnostics (Patiala) Private Limited	Wholly Owned Subsidiary
7	KDPL Diagnostics (Sas Nagar) Private Limited	Wholly Owned Subsidiary
8	Krsnaa Retail Private Limited	Wholly Owned Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditor referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We draw attention to Note No. 7 of the unaudited financial results in respect of additions made by the Income Tax Authorities, consequent to an assessment order passed and a demand raised on the Company for the assessment year (“AY”) 2022-23 in relation to search assessment proceedings conducted under section 132(1) and section 133A of the Income Tax Act, 1961. The Holding Company has filed an appeal with the Joint Commissioner (Appeals) or Commissioner of Income Tax (Appeals) against the said Order and has deposited Rs. 39.26 million as tax under protest, as required by law during the half year ended September 30, 2024. As there is uncertainty on the ultimate outcome of the assessment proceedings and the appeal filed by the Holding Company, the impact on the previous period financial statements and on the current period financial results for the quarter and the half year ended September 30, 2024, including income tax, interest and other charges if any, is currently unascertainable.
Our conclusion is not modified in respect of the above matter.
7. We did not review the interim financial statements of one subsidiary included in the Statement, whose interim financial statements reflect total assets of Rs. 12.39 million as at September 30, 2024 and total revenues of Rs. 11.26 million and Rs.11.26 million, total net loss after tax of Rs. 21.88 million and Rs. 24.45 million and total comprehensive loss of Rs. 21.88 million and Rs. 24.45 million, for the quarter ended September 30, 2024, and for the period from April 01, 2024 to September 30, 2024, respectively, and cash inflows (net) of Rs. 1.01 million, for the period from April 01, 2024 to September 30, 2024, as considered in the Statement. These interim financial statements has been reviewed by other auditor whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.



MSKA & Associates

Chartered Accountants

Our conclusion is not modified in respect of the above matter with respect to our reliance on the work done by and report of the other auditor.

For M S K A & Associates

Chartered Accountants

ICAI Firm Registration No.105047W



Vikram Dhanania

Partner

Membership No.: 060568

UDIN: 24060568BKDZKY2338



Place: Mumbai

Date: October 25, 2024

1. Statement of Unaudited Consolidated Financial Results for the quarter and half year ended September 30, 2024

(INR Million, except earnings per share)

Sr. No.	Particulars	Quarter ended			Half year ended		Year ended
		September 30, 2024	June 30, 2024	September 30, 2023	September 30, 2024	September 30, 2023	March 31, 2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income						
	Revenue from operations	1,863.40	1,702.32	1,554.49	3,565.72	2,950.28	6,196.33
	Other income	45.94	73.16	41.58	119.10	83.80	167.96
	Total Income	1,909.34	1,775.48	1,596.07	3,684.82	3,034.08	6,364.29
2	Expenses						
	Cost of material consumed	449.13	429.01	359.16	878.14	636.85	1,410.40
	Employee benefits expense	350.55	330.78	264.39	681.33	493.57	1,114.65
	Finance costs	63.89	53.16	30.63	117.05	50.24	164.88
	Depreciation and amortization expense	222.01	214.66	194.64	436.67	351.99	745.47
	Fees to hospitals and others	173.57	123.41	202.62	296.97	376.48	654.68
	Other expenses	396.15	392.44	410.44	788.60	811.85	1,574.14
	Total Expenses	1,655.30	1,543.46	1,461.88	3,198.76	2,720.98	5,664.22
3	Profit before tax (1) - (2)	254.04	232.02	134.19	486.06	313.10	700.07
4	Tax expenses						
	Income Tax charge	50.85	40.46	16.97	91.31	55.16	114.42
	Income Tax charge relating to earlier year	-	-	-	-	(6.26)	(6.41)
	Deferred tax charge/(credit)	7.23	12.35	12.26	19.58	12.81	23.69
	Total tax expenses	58.08	52.81	29.23	110.89	61.71	131.70
5	Profit for the period (3) - (4)	195.96	179.21	104.96	375.17	251.39	568.37
6	Other comprehensive income						
	Items that will not be reclassified subsequently to profit and loss						
	Re-measurement gains / (losses) on defined benefit plans	(0.67)	(0.72)	2.07	(1.39)	4.14	(1.78)
	Income tax effect	0.17	0.18	(0.54)	0.35	(1.06)	0.45
	Total other comprehensive income for the period	(0.50)	(0.54)	1.53	(1.04)	3.08	(1.33)
7	Total comprehensive income for the period, net of tax (5+6)	195.46	178.67	106.49	374.13	254.47	567.04
	Profit for the quarter/year						
	Attributable to:						
	Equity Holders of the Holding Company	195.96	179.21	104.96	375.17	251.39	568.37
	Non Controlling Interests	-	-	-	-	-	-
		195.96	179.21	104.96	375.17	251.39	568.37
	Total other comprehensive income / (loss) for the period attributable to:						
	Equity Holders of the Holding Company	(0.50)	(0.54)	1.53	(1.04)	3.08	(1.33)
	Non Controlling Interests	-	-	-	-	-	-
		(0.50)	(0.54)	1.53	(1.04)	3.08	(1.33)
	Total comprehensive income for the period attributable to:						
	Equity Holders of the Holding Company	195.46	178.67	106.49	374.13	254.47	567.04
	Non Controlling Interests	-	-	-	-	-	-
		195.46	178.67	106.49	374.13	254.47	567.04
8	Paid-up equity share capital (Face Value of Rs. 5/- each)	161.45	161.45	156.99	161.45	156.99	161.45
	Other equity						7,936.57
	Earnings per share (Not annualised for quarters):						
	Basic (Rs.)	6.07	5.55	3.35	11.62	8.01	17.90
	Diluted (Rs.)	5.92	5.46	3.23	11.38	7.73	17.31

For and on behalf of Board of Directors
Krsnaa Diagnostics Limited



Rajendra Mutha
Chairman & Whole-time Director
DIN: 01066737

2. Statement of Unaudited Consolidated Assets & Liabilities as at September 30, 2024.

(INR Million)

Particulars	As at September 30, 2024 (Unaudited)	As at March 31, 2024 (Audited)
I. ASSETS		
Non-current assets		
Property, plant and equipment	6,863.38	6,447.21
Capital work-in-progress	34.76	98.45
Intangible assets	23.24	24.34
Financial assets		
Investments	2.91	2.91
Other financial assets	1,233.97	326.64
Deferred tax asset (net)	24.54	16.31
Other non-current assets	589.54	591.41
Total non-current assets	8,772.33	7,507.27
Current assets		
Inventories	306.87	358.07
Financial assets		
Trade receivables	2,434.72	1,762.92
Cash and cash equivalents	112.79	23.75
Bank balances other than cash and cash equivalent	513.44	511.70
Other financial assets	626.95	1,430.75
Other current assets	178.29	124.67
Total current assets	4,173.06	4,211.86
Total Assets	12,945.39	11,719.13
II. EQUITY AND LIABILITIES		
Equity		
Equity share capital	161.45	161.45
Other equity	8,246.17	7,936.57
Total equity	8,407.62	8,098.02
Liabilities		
Non-current liabilities		
Financial liabilities		
Borrowings	27.50	55.00
Lease Liabilities	321.20	363.81
Other financial liabilities	160.44	205.59
Employee benefit obligations	20.53	17.75
Deferred Tax Liabilities	196.82	164.30
Total non-current liabilities	726.49	806.45
Current liabilities		
Financial liabilities		
Borrowings	1,662.19	1,012.21
Lease Liabilities	149.99	166.86
Trade payables		
i) Total outstanding dues of micro enterprises and small enterprises	10.89	9.15
ii) Total outstanding dues of creditors other than micro enterprise and small enterprise	917.24	814.04
Other financial liabilities	980.62	678.19
Other current liabilities	35.71	91.95
Employee benefit obligations	54.64	42.26
Current liabilities	3,811.28	2,814.66
Total Liabilities	4,537.77	3,621.11
Total Equity and Liabilities	12,945.39	11,719.13

For and on behalf of Board of Directors
Krsnaa Diagnostics Limited



Rajendra Mutha
Chairman & Whole-time Director
DIN: 01066737

Place: Goa
Date: October 25, 2024

3. Statement of Unaudited Consolidated Cashflows for the half year ended September 30, 2024

(INR Million)

Particulars	Half Year Ended		Year Ended
	September 30, 2024	September 30, 2023	March 31, 2024
	(Unaudited)	(Unaudited)	(Audited)
A. Cash flow from operating activities			
Profit before Tax	486.06	313.10	700.07
Adjustments for:			
Depreciation and amortization expenses	436.67	351.99	745.47
Share Based Payment Expense	21.69	2.60	9.01
Finance cost	117.05	50.24	164.88
Interest income on deposits	(75.52)	(76.06)	(152.33)
Loss / (Gain) on sale/disposal of Property, Plant & Equipment	0.29	(0.01)	0.53
Provision for credit Impaired	2.00	-	3.40
Amortisation of deferred revenue	(0.06)	(0.74)	(1.19)
Amortisation of prepaid rent	8.33	-	(56.51)
Interest income on other financial assets	(7.85)	-	(14.07)
Operating profit before working capital changes	988.66	641.12	1,399.26
Changes in working capital			
Increase/(Decrease) in trade payables	90.07	411.10	156.69
(Increase)/Decrease in inventories	51.20	(113.56)	(107.33)
(Increase)/Decrease in trade receivables	(674.02)	(858.19)	(1,035.49)
Increase/(Decrease) in other current liabilities	(56.53)	15.70	70.32
Increase/(Decrease) in other non current liabilities	0.07	(0.07)	-
Increase/(Decrease) in other current financial liabilities	15.40	12.75	41.07
Increase/(Decrease) in other non current financial liabilities	-	(17.94)	23.72
Increase/(Decrease) in employee payables	13.77	11.11	24.46
(Increase)/Decrease in other current financial assets	58.16	(36.57)	(58.09)
(Increase)/Decrease in non current financial assets	(87.37)	34.05	4.05
(Increase)/Decrease in other current assets	(38.74)	(28.75)	2.56
(Increase)/Decrease in other non current assets	(87.44)	(0.88)	(89.75)
Cash generated from operations	273.23	69.87	431.47
Income tax paid (Net of refunds)	(76.17)	(68.54)	(188.02)
Net cash flows generated from operating activities (A)	197.06	1.33	243.45
B. Cash flow from Investing activities			
Payment for property, plant and equipment and intangible assets	(546.43)	(899.37)	(1,938.87)
Proceeds from sale of property, plant and equipment and intangible assets	0.39	0.04	8.87
Investment in term deposits with banks	(113.03)	463.64	537.40
Interest received	112.01	49.34	103.83
Net cash flow (used) in investing activities (B)	(547.06)	(386.35)	(1,288.77)
C. Cash flow from Financing activities			
Proceeds from exercise of ESOP	-	-	231.92
Proceeds from Short Term borrowings (net)	649.98	534.14	957.21
Repayment of Long Term borrowings	(27.50)	-	(55.00)
Payment of Lease Liabilities	(82.72)	(41.49)	(81.90)
Dividend payment/TDS on Dividend to equity shareholders	(5.27)	-	(86.29)
Interest paid	(95.45)	(31.61)	(124.07)
Net cash flow generated from/(used) in financing activities (C)	439.04	461.04	841.87
Net Increase/(Decrease) in cash and cash equivalents (A+B+C)	89.04	76.02	(203.45)
Cash and cash equivalents at the beginning of the period	23.75	227.20	227.20
Cash and cash equivalents at the end of the period	112.79	303.22	23.75
Cash and cash equivalents comprise:			
Balances with banks			
On current accounts	95.51	288.95	10.42
Cash on hand	17.28	14.27	13.33
Total cash and bank balances at end of the year	112.79	303.22	23.75



For and on behalf of Board of Directors
Krsnaa Diagnostics Limited

Rajendra Mutha
Chairman & Whole-time Director
DIN: 01066737

Place: Goa
Date: October 25, 2024

Krsnaa Diagnostics Limited

CIN:L74900PN2010PLC138068

Notes to Unaudited Consolidated Financial Results:

4. These Consolidated unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on October 25, 2024.

5. The above Statement has been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) 2015, as amended.

6. The Group's operations predominantly relate to providing diagnostic services in radiology and pathology services. The Chief Operating Decision Maker (CODM) reviews the operations of the Group as one operating segment. Hence, no separate segment information has been furnished herewith.

7. Pursuant to search and seizure proceedings initiated under the provisions of section 132(1) and section 133A of the Income Tax Act, 1961 on the holding company on July 20, 2022, an assessment order dated March 31, 2024 u/s 143(3) of the Income Tax Act, 1961 ("the Order"), has been received by the holding company for the assessment year ("AY") 2022-23. The Income tax authorities have allegedly made additions on account of undisclosed income and disallowance of certain deductions claimed by the holding company in the tax returns filed in respect of AY 2022-23 and raised a demand of Rs.196.3 million.

The holding company has provided the requisite disclosure to the stock exchange on July 29, 2022, with respect to the search operations, and on April 1, 2024, with respect to the receipt of the Order in accordance with Regulation 30 of the SEBI (LODR) Regulations, 2015 (as amended). The holding company has filed an appeal with the Joint Commissioner (Appeals) or Commissioner of Income-Tax (Appeals) against the Order on April 29, 2024, and have paid tax under protest on August 6, 2024, amounting to Rs. 39.26 million.

The management of the holding company, based on available information, underlying evidence and opinion from tax consultants and experts, is of the view that the said demand is not tenable and will not have any material impact on the holding company's financial position as of September 30, 2024, and on its performance for the quarter and half year ended on that date.

8. Previous period/year figures have been regrouped/ rearranged wherever considered necessary.

Place: Goa

Date: October 25, 2024



For and on behalf of Board of Directors
Krsnaa Diagnostics Limited

Rajendra Mutha
Chairman & Whole-time Director
DIN: 01066737